Nudge Raises $100M Series A for Non-Invasive Focused Ultrasound BCI
Summary
Nudge has raised $100 million in a Series A financing to develop its non-invasive focused ultrasound brain interface platform for stimulating and imaging the brain without surgery. The company's approach uses focused ultrasound to both read neural activity and modulate brain function with precision, offering potential applications in mental health, cognitive enhancement, and neurological disease treatment. The funding will accelerate platform development and early clinical validation studies.
Why it matters
Nudge's funding underscores growing investor enthusiasm for focused ultrasound as a next-generation BCI modality that bridges the gap between non-invasive and invasive approaches. Unlike EEG or TMS, focused ultrasound can reach deep brain structures with millimeter precision while remaining completely non-invasive. The $100M Series A positions Nudge as a serious contender in the increasingly competitive non-invasive BCI landscape alongside ultrasound-based approaches from companies like SonoMind and Merge Labs.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial